Risk stratifi cation of Barrett ' s esophagus (BE) patients based on clinical and endoscopic features may help to optimize surveillance practice for esophageal adenocarcinoma (EAC) development. The aim of this study was to investigate patient symptoms and endoscopic features at index endoscopy and risk of neoplastic progression in a large population-based cohort of BE patients.
INTRODUCTION
Barrett ' s esophagus (BE), metaplasia of the normal esophageal squamous epithelium into specialized columnar epithelium, is rising in incidence (over and above endoscopy rates) throughout the Western world ( 1 -3 ) . Th e importance of BE lies in the fact that it is a precursor of esophageal adenocarcinoma (EAC), a tumor that has a poor prognosis ( 4, 5 ) . Th e opportunity for detection of BE, and potential prevention of adenocarcinoma, has led gastroenterology organizations worldwide to endorse endoscopic surveillance of BE patients ( 6, 7 ) . However, endoscopic surveillance of BE is controversial because of ongoing debate as to its cost eff ectiveness ( 8 ) . Identifying patients at greatest risk of neoplastic progression, which only occurs in a minority of cases ( 9 -11 ) , is a key priority in order to optimize the usefulness of such surveillance programs.
BE and EAC are both thought to result from repeated exposure to bile and gastric acid in the distal esophagus ( 12 ) . A landmark publication from a Swedish population-based case -control study demonstrated that individuals reporting weekly refl ux symptoms were at a sevenfold increased risk of EAC ( 13 ) . Moreover, a doseresponse relationship with frequency of symptoms was also noted ( 13 ) . However, in contrast to the link between symptoms in the general population and development of EAC, the relationship between refl ux symptoms experienced at presentation of BE and subsequent risk of neoplastic progression is less certain ( 14 ) . BE is thought to represent an adaptive response to acid-induced injury and ulceration, and therefore it is not unexpected that a substantial proportion of BE patients purport to be asymptomatic ( 15 ) . Th e relevance of refl ux, and other, symptoms present BE at diagnosis for stratifi cation of cancer risk and associated need for surveillance is yet to be determined. Stratifi cation of patients for surveillance based on other endoscopic fi ndings at BE presentation, such as esophagitis and ulceration, has also been suggested by some studies ( 14, 16 ) . However, previous studies seeking to explore the association between these fi ndings and EAC risk in a sequential manner have been limited by relatively small numbers of outcomes or lack of adjustment for known confounders, such as the presence of low-grade dysplasia ( 14, 16 ) .
Th e aim of this study was to examine the association between symptoms and endoscopic features in incident BE patients and their risk of neoplastic progression in a large population-based cohort.
METHODS

Data collection
BE patients with specialized intestinal metaplasia were identifi ed from the Northern Ireland BE register, a population-based register of all individuals aged ≥ 16 years who were diagnosed with columnar-lined epithelium of the esophagus since 1993 in the province ( 1 ) . Th e register excludes BE cases with prevalent high-grade dysplasia (HGD), but retains those with indefi nite or low-grade dysplasia at incident BE diagnosis. Between 1993 and 2005, 4,717 BE patients were diagnosed with specialized intestinal metaplasia, of whom 3,167 (comparable in age and sex distribution to all specialized intestinal metaplasia patients) underwent a hospital case note review. Th e hospital notes of these patients were retrospectively reviewed by one of three trained data abstractors between March 2005 and March 2010. A standardized electronic pro forma in Microsoft Access was utilized to extract demographic, medical, symptom, treatment, and clinical information from records corresponding to the patient ' s incident diagnosis of BE. Th e process of this case note review has been previously described for outcomes up to the end of 2008 ( 17 ) . Th e Northern Ireland BE register has subsequently been populated with the Health and Social Care number (a unique identifi er within the UK National Health Service). Th is allowed identifi cation of a small number of duplicate patients ( n = 19, 0.6 % ), leaving 3,148 BE patients in the current analysis.
Confi rmation of outcome diagnosis
Details of the linkage process and confi rmation of BE patients who progressed to develop cancer and HGD in this cohort have been published elsewhere ( 9 ) . Briefl y, the Northern Ireland BE register was linked to the Northern Ireland Cancer Registry to identify patients diagnosed with incident esophageal and gastric cardia adenocarcinomas or unspecifi ed cancers of the esophagus on or before 31 December 2010. Esophageal squamous cell carcinomas were excluded. Cases of HGD were identifi ed from an electronic and manual review of all esophageal biopsy reports within Northern Ireland up to 31 December 2010. Only cancers or HGD diagnosed at least 6 months aft er an incident BE diagnosis were included to minimize the potential for prevalent cancers to have infl uenced symptom experience and endoscopic features. Th e Northern Ireland BE register was matched to the General Registrar ' s Offi ce in Northern Ireland to identify deaths occurring over the same time period.
Statistical analysis
Independent t -tests and χ 2 tests were applied to compare continuous and categorical variables, respectively, between BE patients who progressed to cancer or HGD and those who did not progress. Where the report relating to an incident BE diagnosis did not mention a symptom or endoscopic feature, for example gastrointestinal bleeding, that patient was presumed to not have experienced that symptom or feature and was recoded accordingly. Cox proportional hazards models were applied to investigate the association between reported symptoms and endoscopic features at incident BE diagnosis and the risk of progression to cancer or HGD. Assumptions for Cox proportional hazards models were checked by visual inspection of the Kaplan -Meier plots. Both unadjusted and adjusted models were applied using a censor date as the date of death, date of cancer or HGD diagnosis, or 31 December 2010. In the adjusted models, included confounders were age, sex, presence of low-grade dysplasia, socioeconomic status (refl ected by area-based income deprivation quintiles), tobacco smoking status (never / former / current / unknown), and Barrett ' s segment length, based on a priori knowledge of these risk factors for EAC development. We also tested adjustment for ever use of medications including nonsteroidal anti-infl ammatory drugs, aspirin, proton pump inhibitors, and H2 antagonists, but these did not signifi cantly alter the results shown. Stratifi ed analyses were conducted for cancer-only outcomes by follow-up duration, age categories, Barrett ' s segment length, smoking status, proton pump inhibitor usage, and dysplastic status. Tests for interactions were conducted using the likelihood ratio test. In addition, sensitivity analyses excluding outcomes diagnosed within 1 year of follow-up were conducted to minimize the likelihood of reverse causation from undetected prevalent neoplasms. All statistical analyses were conducted using Intercooled Stata Version 11 (StataCorp, College Station, TX).
RESULTS
A total of 3,148 BE patients were followed for a mean ( ± s.d.) of 8.9 ( ± 4.1) years (range 0.5 -18.0 years). During this period, 128 patients progressed to develop HGD ( n = 36) or EAC ( n = 92). Demographic, lifestyle, and clinical data of these patients are displayed in Table 1 . Progressors were more likely to be male, aged
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60 -70 years at incident BE, have long-segment BE, low-grade dysplasia, and have ever smoked tobacco compared with nonprogressors. No signifi cant diff erences were observed between progressors and nonprogressors in terms of socioeconomic status or usage of certain medications (nonsteroidal anti-infl ammatory drugs, aspirin, H2 antagonists, or proton pump inhibitors) at their incident BE diagnosis. Table 2 outlines the association between esophageal features noted at endoscopy and the risk of neoplastic progression in incident BE. Long-segment Barrett ' s was associated with a sevenfold increased risk of progression, although segment length was unknown in approximately half of the patients. Only two patients with short-segment BE progressed to HGD, with none developing EAC during the study time period. Progressors were more likely to have had a Barrett ' s ulcer at their incident diagnosis compared with nonprogressors (hazard ratio (HR) 1.99; 95 % confi dence interval (CI): 1.26 -3.15), even aft er adjustment for confounders (HR 1.72; 95 % CI: 1.08 -2.76). Other endoscopic features, including esophagitis, esophageal stricture, and presence of hiatus hernia, were unrelated to progression risk. Largely similar results were observed in analysis including only cancer progressors ( Table 2 ) .
Th e association between reported symptoms at incident BE diagnoses and the risk of progression is shown in Table 3 . Incident BE patients reporting gastroesophageal refl ux symptoms had a reduced risk of cancer progression (HR 0.62; 95 % CI: 0.41 -0.95). Th is was equivalent to asymptomatic patients having a 61 % increased risk of EAC progression, aft er adjustment for confounders (HR 1.61; 95 % CI: 1.05 -2.46). Th e association was weaker when considering HGD and EAC outcomes combined. BE patients reporting ≥ 5 kg loss in body weight at their incident diagnosis were at a signifi cantly increased risk of cancer progression (HR 2.01; 95 % CI: 1.01 -3.98) compared with patients who did not report experiencing weight loss. No other reported symptoms were associated with progression risk. Th e a priori sensitivity and stratifi ed analyses . As shown in Supplementary Figure S1 online, the magnitude of the inverse association between refl ux symptoms and EAC progression risk remained consistent across strata of follow-up time, age categories, BE segment length, smoking status, proton pump inhibitor usage, and in nondysplastic BE at index diagnosis. Small numbers precluded meaningful sensitivity and stratifi ed analyses for weight loss and Barrett ' s ulceration fi ndings. Nevertheless, it should be noted that the direct association between a reported weight loss of ≥ 5 kg and cancer progression remained even up to 5 years aft er incident BE diagnosis (HR 3.09; 95 % CI: 1.27 -7.53). All previously observed associations remained largely unaltered in sensitivity analyses of patients whose esophageal HGD or cancer was diagnosed at least 1 year aft er their incident BE diagnosis ( Table 4 ).
DISCUSSION
In this study, based on one of the largest series of progressors from BE to HGD / EAC in the world, the presence of long-segment Barrett ' s carried a sevenfold increased risk of progression. Smaller, but statistically signifi cant, increased risks of progression were also noted for patients with Barrett ' s ulceration and for those reporting substantial weight loss at their incident diagnosis. Gastroesophageal refl ux symptoms were associated with a decreased risk of cancer progression, whereas no other reported symptoms or endoscopic fi ndings were predictive of progression in these patients. Because of the relatively low proportion of BE patients who progress to HGD / EAC ( 9 ), research eff orts are attempting to identify factors that may streamline the entry into surveillance and its frequency. Th e relevance of both symptoms at presentation and endoscopic fi ndings at BE diagnosis are of importance to clinicians when considering entry into surveillance and risk of malignant progression with individual patients ( 18 ) .
A study of 27 BE patients undergoing 24 h esophageal pH monitoring has previously identifi ed a strong positive correlation between the duration of acid exposure and Barrett ' s segment length (19) . One of the key fi ndings from the current study was that patients with long-segment BE (defi ned as ≥ 3 cm) had a sevenfold increased risk of progression to HGD / EAC compared with short-segment BE. Our analysis was somewhat limited though, as Barrett ' s segment length was unknown in almost half of patients. Th e fi nding that longer segment length corresponds to increased progression risk concurs with results from several other studies ( 20 -22 ) and previous reports from this cohort ( 9 ) . Th e lack of progression in short-segment BE cases suggests that there would be limited benefi ts to entering these patients into current surveillance protocols, and that longer surveillance intervals or additional criteria for inclusion in surveillance programs may be warranted ( 23 ).
In addition, our fi ndings demonstrated that the presence of Barrett ' s ulceration, but not ulceration elsewhere in the esophagus, increased the risk of progression to HGD / EAC. Because our study is large, it builds upon observations from previous smaller studies, aff ording greater specifi city of fi ndings. In an Australian study of 353 BE patients, of whom 13 progressed to HGD / EAC over a 20-year follow-up period, the combined presence of severe esophagitis, nodularity, Barrett ' s ulceration, and / or stricture was deemed to elevate the risk of progression in age-and sex-adjusted analysis ( 16 ) . A small study reported by Switzer-Taylor e t al . ( 24 ) , in which 9 esophageal cancers were detected among a sample of 212 BE patients during 13 years of follow-up, noted that half of progressors had ulceration at their index endoscopy. A Dutch study of 713 patients, incorporating 26 progressors, found BE " irregularities " (incorporating erosions, ulcers, and nodules) to carry a nonsignifi cant twofold increased risk of progression in multivariate models, whereas esophagitis was a determinant of progression ( 14 ) . A recent report from the North-Eastern Italian BE register also noted ulceration or nodularity to be associated with a heightened risk of HGD / EAC in an analysis of 22 progressors ( 25 ) .
Case -control studies have identifi ed that refl ux symptoms in the general population are linked with esophageal carcinogenesis ( 12, 26, 27 ) . Th is is consistent with the well-established role of refl ux in BE development ( 28, 29 ) . In contrast, asymptomatic BE patients in this study were found to be at greater risk of EAC 
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parities in symptom recognition, as has been postulated by others ( 36, 37 ) . Th e relationship between symptoms and acid exposure is an important area for further research, as our fi ndings suggest that subjectively reported symptoms would not be useful in stratifying high-risk BE patients for surveillance. Moreover, our results also raise questions over symptom control being the desired end point in BE management, as has been highlighted by Sarela et al. ( 38 ) . Asymptomatic patients may still require antiacid treatments. In addition, we observed that weight loss of ≥ 5 kg in BE patients was associated with a signifi cantly increased risk of progression. It is unlikely that such weight loss was refl ecting subclinical disease, or the development of more aggressive tumors among BE progressors, as progression risk remained elevated up to 5 years aft er BE diagnosis. Such substantial weight loss could refl ect prior overweight / obesity, a known risk factor for esophageal adenocarcinoma ( 12, 39 ) . However, our fi ndings require replication in future prospective studies. Individuals should continue to be advised to maintain a normal body weight in order to reduce their risk of developing EAC ( 39,40 ) . progression, and in whom a recent review highlighted to have an unknown prognosis ( 30 ) . In turn, these fi ndings point to the presence of refl ux symptoms at the time of diagnosis of BE diagnosis as being inversely associated with progression risk. It is highly unlikely that this refl ects a " true " decreased risk, as mechanistic evidence supports the carcinogenic eff ects of chronic acid exposure in Barrett ' s cell lines, such as infl ammation and induction of chromosomal aneuploidy ( 31 ) , that is predictive of BE progression risk ( 32 ) .
Rather, it is more plausible that a poor correlation exists between patient perception of refl ux and actual refl uxate in the esophagus. Symptoms of gastroesophageal refl ux disease are not predictive of BE presence ( 33 ) , and it has long been known that there is reduced esophageal acid sensitivity in columnar vs. squamous mucosa ( 34 ), A small pain-stimulation study has also demonstrated that BE patients are hyposensitive to heat in both the normal squamous and the metaplastic epithelium of their esophagus compared with normal controls ( 35 ) , and hence may be less likely to report symptoms. Our results suggested this was not refl ective of age dis- BE, Barrett's esophagus; CI, confi dence interval; EAC, esophageal adenocarcinoma; GI bleeding, gastrointestinal bleeding. Adjustments: age groups (16 to < 40 / 40 to < 50 / 50 to < 60 / 60 to < 70 / 70 to < 80 / ≥ 80 years), sex (male / female), presence of low-grade dysplasia (yes / no / unknown), income deprivation quintile (I / II / III / IV / V / unknown), Barrett's segment length (long / short or unknown), and smoking status (never / former / current / unknown).
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WHAT IS NEW HERE
3 No short-segment Barrett ' s cases developed esophageal adenocarcinoma during the study period.
3 Ulceration in the Barrett ' s segment was associated with an increased risk of neoplastic progression.
3 Absence of refl ux symptoms does not confer a reduced risk of malignant progression.
Our study has several strengths, including its large size and population-based setting in the Northern Ireland BE register, providing generalizability to all BE patients in the province. Although information was collected retrospectively, it was retrieved from hospital case notes relating to a patient ' s incident BE diagnosis. Th erefore, this is the largest study to date that has investigated endoscopic fi ndings and symptom experiences and progression risk in a sequential manner. In addition, we were able to control for a number of known confounders in our analysis.
Th ere are some limitations to our analysis. It is possible that some patients did not report all of their symptoms to clinicians in order for them to be recorded in the case notes. Th e potentially subjective nature of symptom reporting means that results for refl ux symptoms and weight loss should be interpreted with caution. Our analysis of Barrett ' s segment length was relatively crude as we did not have exact length in cm for most patients and length was unknown for a considerable proportion. It is also plausible that there may be some residual confounding from unaccounted variables in our analysis.
In conclusion, BE patients presenting with long-segment Barrett ' s or Barrett ' s ulceration have an increased risk of progressing to HGD / EAC and should be considered for more intense surveillance. Th e absence of refl ux symptoms at diagnosis is not associated with a reduced risk of malignant progression, and may carry an increased risk of progression.
